Avodart, Dutasteride News

A study published Online First in The Lancet has found that a common medication used to treat enlargement of the prostate, may also reduce the need for treatments that pose risks of incontinence and impotence and delay growth of early-stage prostate cancer.

A drug that is commonly used to treat men with enlarged prostates may also delay the growth of prostate cancer, according to a new study.

TUESDAY, Jan. 24 -- New research suggests that Avodart, a drug used to treat an enlarged prostate gland, may help slow the progression of early stage prostate cancer, reducing the need for aggressive treatment in some men.

The 5-reductase inhibitor dutasteride inhibited the progression of low-risk prostate cancer in a trial conducted by the drug's manufacturer and published in the Lancet .

Dutasteride, a drug that is commonly used to treat enlargement of the prostate, might also slow the growth of early-stage prostate cancer and reduce the need for potentially debilitating treatments that carry risks of impotence and incontinence, according to an article published Online First in the Lancet .

Newswise - - For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr.

Dr. Neil Fleshner is shown in a handout photo. A class of drug long used to treat prostate enlargement appears to have benefits for men diagnosed with low-risk, localized prostate cancer - delaying disease progression and reducing patients' anxiety, a Canadian-led international study has found.

Brian Lindshield, assistant professor of human nutrition, is helping men make more informed diet decisions by studying foods and dietary supplements that may reduce the risk of prostate cancer.